APA (7th ed.) Citation

Yufan Huang, Maojin You, Qundan Wu, & Ruijia Chen. (2023). Cost-effectiveness analysis of zolbetuximab plus mFOLFOX6 as the first-line treatment for CLDN18.2-positive, HER2-negative advanced gastric or Gastroesophageal Adenocarcinoma. Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Yufan Huang, Maojin You, Qundan Wu, and Ruijia Chen. Cost-effectiveness Analysis of Zolbetuximab Plus MFOLFOX6 as the First-line Treatment for CLDN18.2-positive, HER2-negative Advanced Gastric or Gastroesophageal Adenocarcinoma. Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Yufan Huang, et al. Cost-effectiveness Analysis of Zolbetuximab Plus MFOLFOX6 as the First-line Treatment for CLDN18.2-positive, HER2-negative Advanced Gastric or Gastroesophageal Adenocarcinoma. Frontiers Media S.A., 2023.